ENTA - CIK 0001177648
The table below shows ENANTA PHARMACEUTICALS INC's balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2024 | Q3 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $34.93M | $37.44M | $44.81M | $60.21M | $84.35M | $35.77M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | $7.81M | $8.49M | $8.33M | $6.79M | $7.72M | $8.18M |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $178.41M |
| $198.68M |
| $222.71M |
| $242.86M |
| $268.14M |
| $286.58M |
| Property, plant & equipment | $33.11M | $34.31M | $36.62M | $37.57M | $37.37M | $25.05M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $314.70M | $329.50M | $301.03M | $322.99M | $348.64M | $398.82M |
| Accounts payable | $4.36M | $1.89M | $3.55M | $4.76M | $4.73M | $10.68M |
| Total current liabilities | $46.44M | $44.73M | $44.55M | $45.95M | $49.05M | $58.23M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $198.12M | $202.91M | $221.75M | $229.46M | $236.83M | $249.91M |
| Retained earnings | -$429.96M | -$416.87M | -$386.23M | -$367.97M | -$345.33M | -$294.22M |
| Total equity | $116.59M | $126.59M | $79.28M | $93.54M | $111.82M | $148.91M |